Page last updated: 2024-11-04

vorinostat and Lymphoma, Primary Effusion

vorinostat has been researched along with Lymphoma, Primary Effusion in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Lymphoma, Primary Effusion: A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhatt, S1
Ashlock, BM1
Toomey, NL1
Diaz, LA1
Mesri, EA1
Lossos, IS1
Ramos, JC1

Other Studies

1 other study available for vorinostat and Lymphoma, Primary Effusion

ArticleYear
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell

2013